Scholarlink

Background <p>Chronic low back pain (CLBP) is a highly prevalent and burdensome musculoskeletal disorder globally, significantly impacting individuals’ health and quality of life. This study aimed to evaluate the efficacy and safety of the somatic cell therapies in treating CLBP.</p> Methods <p>All relevant randomized controlled trials (RCTs) in the Cochrane, Embase, PubMed, and Web of Science databases were systematically searched for the meta-analysis. The outcomes consisted of Visual Analogue Scale (VAS) scores, Oswestry Disability Index (ODI) scores, and the incidence of serious adverse events (SAE). Dichotomous outcomes were described as odds ratios (OR) with 95% confidence intervals (CIs), while continuous data were presented as mean difference (MD) with 95% CIs. Statistical analysis was performed with RevMan 5.4 and stata 17 software.</p> Results <p>A total of seven RCTs involving 518 patients were included in the meta-analysis. The results showed that somatic cell therapies were effective in terms of VAS scores [MD = -12.04 (-17.35,-6.72)] and ODI scores [MD = -8.03 (-12.84,-3.22)], while not increasing risk of SAE [OR = 0.70 (0.19, 2.64)].</p> Conclusions <p>Our findings suggested that somatic cell therapy demonstrated significant therapeutic efficacy in the management of CLBP. Future large-scale, multicenter RCTs with extended follow-up durations are warranted to confirm the optimal somatic cell type and dosage regimen for maximal therapeutic benefit.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and safety of somatic cell therapy for chronic low back pain: evidence from the pooled randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月25日

查看全文
  • Zihao Li,
  • Yuming Sun,
  • Shaorong Lei,
  • Yikun Zhang,
  • Hang Lin,
  • Yuanheng Yang,
  • Wuyuan Tan

摘要

Background

Chronic low back pain (CLBP) is a highly prevalent and burdensome musculoskeletal disorder globally, significantly impacting individuals’ health and quality of life. This study aimed to evaluate the efficacy and safety of the somatic cell therapies in treating CLBP.

Methods

All relevant randomized controlled trials (RCTs) in the Cochrane, Embase, PubMed, and Web of Science databases were systematically searched for the meta-analysis. The outcomes consisted of Visual Analogue Scale (VAS) scores, Oswestry Disability Index (ODI) scores, and the incidence of serious adverse events (SAE). Dichotomous outcomes were described as odds ratios (OR) with 95% confidence intervals (CIs), while continuous data were presented as mean difference (MD) with 95% CIs. Statistical analysis was performed with RevMan 5.4 and stata 17 software.

Results

A total of seven RCTs involving 518 patients were included in the meta-analysis. The results showed that somatic cell therapies were effective in terms of VAS scores [MD = -12.04 (-17.35,-6.72)] and ODI scores [MD = -8.03 (-12.84,-3.22)], while not increasing risk of SAE [OR = 0.70 (0.19, 2.64)].

Conclusions

Our findings suggested that somatic cell therapy demonstrated significant therapeutic efficacy in the management of CLBP. Future large-scale, multicenter RCTs with extended follow-up durations are warranted to confirm the optimal somatic cell type and dosage regimen for maximal therapeutic benefit.